Boehringer Ingelheim
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Boehringer Ingelheim sits in the top decile of US sponsors by registered trial count (#70 of 15,742 sponsors by registered trial count).
Boehringer Ingelheim: 515 sponsored US clinical trials, 43 recruiting.
Boehringer Ingelheim sponsors 515 registered US clinical trials on ClinicalTrials.gov, 43 of them currently recruiting, and 388 completed. 227 of these trials are in Phase 3-4 (later-stage) and 237 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pulmonary Disease, Chronic Obstructive, with 13 trials.
Top-decile sponsor footprint
Boehringer Ingelheim ranks in the top decile of sponsors by registered trial count (#70 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
388 of 445 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
515 total, page 2 of 11
DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy
NCT05990738
DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer
NCT06077500
A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3
NCT05916313
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
NCT06066528
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
NCT06077864
A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares
NCT06013969
Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine
NCT05846230
A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer
NCT05846516
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated
NCT05327946
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer
NCT05249426
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
NCT04958239
A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation
NCT04973163
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
NCT04886804
A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)
NCT04111458
Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study
NCT03886246
Comparative Effectiveness of Empagliflozin in the US
NCT03363464
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
NCT07540988
A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)
NCT07366034
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654
A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH
NCT06675929
A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver Problems
NCT06692322
A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy
NCT06528093
Natural History of Netherton Syndrome
NCT05902663
A Study to Test Different Doses of BI 1569912 in People With Depression
NCT06558344
A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
NCT06335303
A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
NCT06360094
A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab
NCT06241573
A Study to Test How Avenciguat (BI 685509) is Taken up in the Body of People With and Without Liver Problems
NCT06272058
A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
NCT05966740
A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)
NCT05865886
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight
NCT06309992
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine
NCT06280235
A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly
NCT06082843
Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma
NCT06058793
A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus
NCT06056024
Developing a Screening Tool for Interstitial Lung Disease in People With Rheumatoid Arthritis Using Risk Factors
NCT05855109
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
NCT06066515
A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
NCT06006585
A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease
NCT05970640
Describing Patient With DME, Their Patient Journey and Disease Progression
NCT05966753
Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung Disease
NCT05957198
A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome
NCT05856526
A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer
NCT05839600
Patients With Geographic Atrophy and Their Patient Journey in the United States (US)
NCT05891275
Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients
NCT05870956
Study of Progression to Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Incidence/Management and Treatment
NCT05875532
Dose Reduction and Discontinuation With Anti-Fibrotic Medications
NCT05779007
Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa
NCT05819398
A Study to Test How BI 690517 is Taken up in the Body of People With and Without Liver Problems
NCT05731908
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 94 |
| Phase 2 | 143 |
| Phase 3 | 185 |
| Phase 4 | 42 |
Therapeutic Areas
What is open in the Boehringer Ingelheim pipeline
43 recruiting of 515 indexed (8% open); 388 completed (75%).
Phase mix: 227 late (III/IV) vs 237 early (I/II) (balanced across stages).
Top condition: Pulmonary Disease, Chronic Obstructive (13 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Boehringer Ingelheim: open-pipeline peers nationwide
Peers matched on 515 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
Boehringer Ingelheim sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 515 trials (± recruiting share)
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 523 trials · 13% recruiting
- AbbVie · 526 trials · 21% recruiting
- Gilead Sciences · 504 trials · 5% recruiting
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Acrotech Biopharma · 8% recruiting · 24 trials
- Atlanta VA Medical Center · 8% recruiting · 12 trials
- Beacon Therapeutics · 8% recruiting · 12 trials
- Boston VA Research Institute · 8% recruiting · 12 trials
Related
What to do with this Boehringer Ingelheim page
515 registered trials is a research-attention snapshot, not an endorsement of Boehringer Ingelheim or any single study.
- 43 of Boehringer Ingelheim's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Pulmonary Disease, Chronic Obstructive is the condition Boehringer Ingelheim studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pulmonary Disease, Chronic Obstructive trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Boehringer Ingelheim pipeline card: 515 registered trials from official public datasets.Report a data error.